Michael Becka - Publications

Effects of the chymase inhibitor fulacimstat in diabetic kidney disease-results from the CADA DIA trial.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: July 07, 2020

Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction-Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA MIA) 2 trial.

Journal: American heart journal

Published: November 20, 2019

Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies.

Journal: The Lancet. Haematology

Published: March 22, 2019

Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction-Results of the CHIARA MIA 1 Trial.

Journal: Clinical pharmacology in drug development

Published: September 25, 2018

Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study.

Journal: Thrombosis journal

Published: September 06, 2018

Pharmacokinetics, Safety, and Tolerability of the Novel Chymase Inhibitor BAY 1142524 in Healthy Male Volunteers.

Journal: Clinical pharmacology in drug development

Published: March 07, 2018

Topical administration of regorafenib eye drops: phase I dose-escalation study in healthy volunteers.

Journal: British journal of clinical pharmacology

Published: July 07, 2017

Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study.

Journal: Journal of thrombosis and haemostasis : JTH

Published: December 20, 2016

Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban.

Journal: Clinical pharmacokinetics

Published: September 04, 2013

Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects.

Journal: British journal of clinical pharmacology

Published: May 22, 2013

The effect of food on the absorption and pharmacokinetics of rivaroxaban.

Journal: International journal of clinical pharmacology and therapeutics

Published: March 06, 2013

Open-label, randomized study of the effect of rivaroxaban with or without acetylsalicylic acid on thrombus formation in a perfusion chamber.

Journal: Thrombosis research

Published: February 20, 2013